Current trends in inflammatory and immunomodulatory mediators in sepsis

Journal of Leukocyte Biology

Volumn 93, Issue 3, 2013, Pages 329-342

  Aziz, Monowar ^a   Jacob, Asha ^a   Yang, Weng Lang ^a   Matsuda, Akihisa ^a   Wang, Ping ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Cytokines; Inflammation; Innate and adaptive immunity; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CASPASE 3; CASPASE 7; CD14 ANTIGEN; ENDOTHELIN 1; FINGOLIMOD; GAMMA INTERFERON; GHRELIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 8; LACTADHERIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL 2; RESISTIN; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; BIOACCUMULATION; CD4+ CD25+ T LYMPHOCYTE; COMPETITIVE INHIBITION; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MAST CELL; NATURAL KILLER CELL; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERITONITIS; PHAGOCYTOSIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; UPREGULATION;

ADAPTIVE IMMUNITY; ANIMALS; CHEMOKINES; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INFECTION; INFLAMMATION; INFLAMMATION MEDIATORS; NEUTROPHIL ACTIVATION; NEUTROPHILS; SEPSIS;

EID: 84874509753     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0912437     Document Type: Review

References (158)

1. Lever, A., Mackenzie, I. (2007) Sepsis: definition, epidemiology, and diagnosis. BMJ 335, 879-883.
2. Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont. G., Carcillo, J., Pinsky, M. R. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310.
3. Mokart, D., Leone, M., Sannini, A., Brun, J. P., Tison, A., Delpero, J. R., Houvenaeghel, G., Blache, J. L., Martin, C. (2005) Predictive perioperative factors for developing severe sepsis after major surgery. Br. J. Anaesth. 95, 776-781.
4. Bognar, Z., Foldi, V., Rezman, B., Bogar, L., Csontos, C. (2010) Extravascular lung water index as a sign of developing sepsis in burns. Burns 36, 1263-1270.
5. Cai, B., Deitch, E. A., Ulloa, L. (2010) Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm. 2010, 642462.
6. Haglund, U. (1994) Gut ischaemia. Gut 1 (Suppl.), S73-S76.
7. Oberholzer, A., Oberholzer, C., Moldawer, L. L. (2001) Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16, 83-96.
8. Ayala, A., Chaudry, I. H. (1996) Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock 6 (Suppl. 1), S27-S38.
9. Opal, S. M., Huber, C. E. (2002) Bench-to-bedside review: Toll-like receptors and their role in septic shock. Crit. Care 6, 125-136.
10. Wang, H., Yang, H., Czura, C. J., Sama, A. E., Tracey, K. J. (2001) HMGB1 as a late mediator of lethal systemic inflammation. Am. J. Respir. Crit. Care Med. 164, 1768-1773.
11. Rittirsch, D., Flierl, M. A., Ward, P. A. (2008) Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 8, 776-787.
12. Dinarello, C. A. (2001) Anti-cytokine therapies in response to systemic infection. J. Investig. Dermatol. Symp. Proc. 6, 244-250.
13. Minnich, D. J., Moldawer, L. L. (2004) Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: progress and pitfalls. Proc. Nutr. Soc. 63, 437-441.
14. Dinarello, C. A., Abraham, E. (2002) Does blocking cytokines in sepsis work? Am. J. Respir. Crit. Care Med. 166, 1156-1157.
15. Vincent, J. L., Abraham, E., Annane, D., Bernard, G., Rivers, E., Van den Berghe, G. (2002) Reducing mortality in sepsis: new directions. Crit. Care 6, S1-S18.
16. O'Brien J. M., Jr., Abraham, E. (2003) New approaches to the treatment of sepsis. Clin. Chest Med. 24, 521-548.
17. Vincent, J. L. (2006) Management of sepsis in the critically ill patient: key aspects. Expert Opin. Pharmacother. 7, 2037-2045.
18. Opal, S. M. (2010) New perspectives on immunomodulatory therapy for bacteraemia and sepsis. Int. J. Antimicrob. Agents 36, S70-S73.
19. Lakhani, S. A., Bogue, C. W. (2003) Toll-like receptor signaling in sepsis. Curr. Opin. Pediatr. 15, 278-282.
20. Ramnath, R. V., Weing, S., He, M., Sun, J., Zhang, H., Bawa, M. S., Bhatia, M. (2006) Inflammatory mediators in sepsis: cytokines, chemokines, adhesion molecules and gases. J. Organ Dysfunction 2, 80-92.
21. Hoesel, L. M., Neff, T. A., Neff, S. B., Younger, J. G., Olle, E. W., Gao, H., Pianko, M. J., Bernacki, K. D., Sarma, J. V., Ward, P. A. (2005) Harmful and protective roles of neutrophils in sepsis. Shock 24, 40-47.
22. Opal, S. M., DePalo, V. A. (2000) Anti-inflammatory cytokines. Chest 117, 1162-1172.
23. Perl, M., Chung, C. S., Garber, M., Huang, X., Ayala, A. (2006) Contribution of anti-inflammatory/immune suppressive processes to the pathology of sepsis. Front. Biosci. 11, 272-299.
24. Weaver, C. T., Hatton, R. D., Mangan, P. R., Harrington, L. E. (2007) IL-17 family cytokines and the expanding diversity of effector T-cell lineages. Annu. Rev. Immunol. 25, 821-852.
25. Venet, F., Chung, C. S., Monneret, G., Huang, X., Horner, B., Garber, M., Ayala, A. (2008) Regulatory T cell populations in sepsis and trauma. J. Leukoc. Biol. 83, 523-535.
26. Carding, S. R., Egan, P. J. (2002) γδ T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2, 336-345.
27. Jiang, H., Chess, L. (2004) An integrated view of suppressor T cell subsets in immunoregulation. J. Clin. Invest. 114, 1198-1208.
28. Rhee, R. J., Carlton, S., Chung, C. S., Lomas, J. L., Cioffi, W. G., Ayala, A. (2003) Inhibition of CD1d activation suppresses septic mortality: a role for NK-T cells in septic immune dysfunction. J. Surg. Res. 115, 74-81.
29. Li, L., Huang, L., Sung, S. S., Lobo, P. I., Brown, M. G., Gregg, R. K., Engelhard, V. H., Okusa, M. D. (2007) NKT cell activation mediates neutrophil IFN-γ production and renal ischemia-reperfusion injury. J. Immunol. 178, 5899-5911.
30. Kelly-Scumpia, K. M., Scumpia, P. O., Weinstein, J. S., Delano, M. J., Cuenca, A. G., Nacionales, D. C., Wynn, J. L., Lee, P. Y., Kumagai, Y., Efron, P. A., Akira, S., Wasserfall, C., Atkinson, M. A., Moldawer, L. L. (2011) B cells enhance early innate immune responses during bacterial sepsis. J. Exp. Med. 208, 1673-1682.
31. Rauch, P. J., Chudnovskiy, A., Robbins, C. S., Weber, G. F., Etzrodt, M., Hilgendorf, I., Tiglao, E., Figueiredo, J. L., Iwamoto, Y., Theurl, I., Gorbatov, R., Waring, M. T., Chicoine, A. T., Mouded, M., Pittet, M. J., Nahrendorf, M., Weissleder, R., Swirski, F. K. (2012) Innate response activator B cells protect against microbial sepsis. Science 335, 597-601.
32. Ward, N. S., Casserly, B., Ayala, A. (2008) The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin. Chest Med. 29, 617-625.
33. Hotchkiss, R. S., Karl, I. E. (2003) The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150.
34. Hotchkiss, R. S., Osmon, S. B., Chang, K. C., Wagner, T. H., Coopersmith, C. M., Karl, I. E. (2005) Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J. Immunol. 174, 5110-5118.
35. Fry T. J., Mackall, C. L. (2005) The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J. Immunol. 174, 6571-6576.
36. Geiselhart, L. A., Humphries, C. A., Gregorio, T. A., Mou, S., Subleski, J., Komschlies, K. L. (2001) IL-7 administration alters the CD4: CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation. J. Immunol. 166, 3019-3027.
37. Moore, K. W., de Waal Malefyt, R., Coffman, R. L., O'Garra, A. (2001) Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683-765.
38. Bingold, T. M., Ziesché, E., Scheller, B., Sadik, C. D., Franck, K., Just, L., Sartorius, S., Wahrmann, M., Wissing, H., Zwissler, B., Pfeilschifter, J., Mühl, H. (2010) Interleukin-22 detected in patients with abdominal sepsis. Shock 34, 337-340.
39. Weber, G. F., Schlautkötter, S., Kaiser-Moore, S., Altmayr, F., Holzmann, B., Weighardt, H. (2007) Inhibition of interleukin-22 attenuates bacterial load and organ failure during acute polymicrobial sepsis. Infect. Immun. 75, 1690-1697.
40. Baekkevold, E. S., Roussigné, M., Yamanaka, T., Johansen, F. E., Jahnsen, F. L., Amalric, F., Brandtzaeg, P., Erard, M., Haraldsen, G., Girard, J. P. (2003) Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 163, 69-79.
41. Alves-Filho, J. C., Sônego, F., Souto, F. O., Freitas, A., Verri W. A., Jr., Auxiliadora-Martins, M., Basile-Filho, A., McKenzie, A. N., Xu, D., Cunha, F. Q., Liew, F. Y. (2010) Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16, 708-712.
42. Gibot, S., Massin, F., Alauzet, C., Montemont, C., Lozniewski, A., Bollaert, P. E., Levy, B. (2008) Effects of the TREM-1 pathway modulation during mesenteric ischemia-reperfusion in rats. Crit. Care Med. 36, 504-510.
43. Knapp, S., Gibot, S., de Vos, A., Versteeg, H. H., Colonna, M., van der Poll, T. (2004) Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. J. Immunol. 173, 7131-7134.
44. Dimopoulou, I., Pelekanou, A., Mavrou, I., Savva, A., Tzanela, M., Kotsaki, A., Kardara, M., Orfanos, S. E., Kotanidou, A., Giamarellos-Bourboulis, E. J. (2012) Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: correlation with monocyte gene expression. J. Crit. Care 27, 294-300.
45. Huang, W., Tang, Y., Li, L. (2010) HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 51, 119-126.
46. Messmer, D., Yang, H., Telusma, G., Knoll, F., Li, J., Messmer, B., Tracey, K. J., Chiorazzi, N. (2004) High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173, 307-313.
47. Grunstein, M. (1990) Histone function in transcription. Annu. Rev. Cell Biol. 6, 643-678.
48. Xu, J., Zhang, X., Pelayo, R., Monestier, M., Ammollo, C. T., Semeraro, F., Taylor, F. B., Esmon, N. L., Lupu, F., Esmon, C. T. (2009) Extracellular histones are major mediators of death in sepsis. Nat. Med. 15, 1318-1321.
49. Lund, S. A., Giachelli, C. M., Scatena, M. (2009) The role of osteopontin in inflammatory processes. J. Cell Commun. Signal. 3, 311-322.
50. Vaschetto, R., Nicola, S., Olivieri, C., Boggio, E., Piccolella, F., Mesturini, R., Damnotti, F., Colombo, D., Navalesi, P., Della Corte, F., Dianzani, U., Chiocchetti, A. (2008) Serum levels of osteopontin are increased in SIRS and sepsis. Intensive Care Med. 34, 2176-2184.
51. Guo, H., Wai, P. Y., Mi, Z., Gao, C., Zhang, J., Kuo, P. C. (2008) Osteopontin mediates Stat1 degradation to inhibit iNOS transcription in a cecal ligation and puncture model of sepsis. Surgery 144, 182-188.
52. Spiegel, S., Milstien, S. (2001) The outs and the ins of sphingosine-1-phosphate in immunity. Nat. Rev. Immunol. 11, 403-415.
53. Puneet, P., Yap, C. T., Wong, L., Yulin, L., Koh, D. R., Moochhala, S., Pfeilschifter, J., Huwiler, A., Melendez, A. J. (2010) SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. Science 328, 1290-1294.
54. Niessen, F., Schaffner, F., Furlan-Freguia, C., Pawlinski, R., Bhattacharjee, G., Chun, J., Derian, C. K., Andrade-Gordon, P., Rosen, H., Ruf, W. (2008) Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 452, 654-658.
55. Serhan, C. N., Chiang, N., Van Dyke, T. E. (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349-361.
56. Park, C. K., Xu, Z. Z., Liu, T., Lu, N., Serhan, C. N., Ji, R. R. (2011) Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. J. Neurosci. 31, 18433-18438.
57. Spite, M., Norling, L. V., Summers, L., Yang, R., Cooper, D., Petasis, N. A., Flower, R. J., Perretti, M., Serhan, C. N. (2009) Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287-1291.
58. Pang, S. S., Le, Y. Y. (2006) Role of resistin in inflammation and inflammation-related diseases. Cell. Mol. Immunol. 3, 29-34.
59. Sundén-Cullberg, J., Nyström, T., Lee, M. L., Mullins, G. E., Tokics, L., Andersson, J., Norrby-Teglund, A., Treutiger, C. J. (2007) Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit. Care Med. 35, 1536-1542.
60. Koch, A., Gressner, O. A., Sanson, E., Tacke, F., Trautwein, C. (2009) Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit. Care 13, R95.
61. Yokota, T., Oritani, K., Takahashi, I., Ishikawa, J., Matsuyama, A., Ouchi, N., Kihara, S., Funahashi, T., Tenner, A. J., Tomiyama, Y., Matsuzawa, Y. (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96, 1723-1732.
62. Li, S., Bao, H. G., Han, L., Liu, L., Wang, X. (2012) Effects of adiponectin on mortality and its mechanism in a sepsis mouse model. J. Invest. Surg. 25, 214-219.
63. Luk, T., Malam, Z., Marshall, J. C. (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J. Leukoc. Biol. 83, 804-816.
64. Moschen, A. R., Kaser, A., Enrich, B., Mosheimer, B., Theurl, M., Niederegger, H., Tilg, H. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 178, 1748-1758.
65. Jia, S. H., Li, Y., Parodo, J., Kapus, A., Fan, L., Rotstein, O. D., Marshall, J. C. (2004) Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J. Clin. Invest. 113, 1318-1327.
66. Cekmez, F., Canpolat, F. E., Cetinkaya, M., Aydinöz, S., Aydemir, G., Karademir, F., Ipcioglu, O. M., Sarici, S. Ü. (2011) Diagnostic value of resistin and visfatin, in comparison with C-reactive protein, procalcitonin and interleukin-6 in neonatal sepsis. Eur. Cytokine Netw. 22, 113-117.
67. Wu, R., Dong, W., Zhou, M., Zhang, F., Marini, C. P., Ravikumar, T. S., Wang, P. (2007) Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am. J. Respir. Crit. Care Med. 176, 805-813.
68. Cheyuo, C., Jacob, A., Wang, P. (2012) Ghrelin-mediated sympathoinhibition and suppression of inflammation in sepsis. Am. J. Physiol. Endocrinol. Metab. 302, E265-E272.
69. Yang, J., Wu, R., Zhou, M., Wang, P. (2010) Human adrenomedullin and its binding protein ameliorate sepsis-induced organ injury and mortality in jaundiced rats. Peptides 31, 872-877.
70. Fowler, D. E., Yang, S., Zhou, M., Chaudry, I. H., Simms, H. H., Wang, P. (2003) Adrenomedullin and adrenomedullin binding protein-1: their role in the septic response. J. Surg. Res. 109, 175-181.
71. Vemulapalli, S., Chiu, P. J., Rivelli, M., Foster, C. J., Sybertz, E. J. (1991) Modulation of circulating endothelin levels in hypertension and endotoxemia in rats. J. Cardiovasc. Pharmacol. 8, 895-903.
72. Ruetten, H., Thiemermann, C. (1996) Effect of selective blockade of endothelin ETB receptors on the liver dysfunction and injury caused by endotoxaemia in the rat. Br. J. Pharmacol. 119, 479-486.
73. Iskit, A. B., Sungur, A., Gedikoglu, G., Guc, M. O. (1999) The effects of bosentan, aminoguanidine and L-canavanine on mesenteric blood flow, spleen and liver in endotoxaemic mice. Eur. J. Pharmacol. 379, 73-80.
74. Matsuda, A., Jacob, A., Wu, R., Zhou, M., Nicastro, J. M., Coppa, G. F., Wang, P. (2011) Milk fat globule-EGF factor VIII in sepsis and ischemia-reperfusion injury. Mol. Med. 17, 126-133.
75. Aziz, M., Matsuda, A., Yang, WL., Jacob, A., Wang, P. (2012) Milk fat globule-epidermal growth factor-factor 8 attenuates neutrophil infiltration in acute lung injury via modulation of CXCR2. J. Immunol. 189, 393-402.
76. Cui, T., Miksa, M., Wu, R., Komura, H., Zhou, M., Dong, W., Wang, Z., Higuchi, S., Chaung, W., Blau, S. A., Marini, C. P., Ravikumar, T. S., Wang, P. (2010) Milk fat globule epidermal growth factor 8 attenuates acute lung injury in mice after intestinal ischemia and reperfusion. Am. J. Respir. Crit. Care Med. 181, 238-246.
77. Mazzucchelli, R., Durum, S. K. (2007) Interleukin-7 receptor expression: intelligent design. Nat. Rev. Immunol. 7, 144-154.
78. Sportès, C., Hakim, F. T., Memon, S. A., Zhang, H., Chua, K. S., Brown, M. R., Fleisher, T. A., Krumlauf, M. C., Babb, R. R., Chow, C. K., Fry, T. J., Engels, J., Buffet, R., Morre, M., Amato, R. J., Venzon, D. J., Korngold, R., Pecora, A., Gress, R. E., Mackall, C. L. (2008) Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 205, 1701-1714.
79. Sereti, I., Dunham, R. M., Spritzler, J., Aga, E., Proschan, M. A., Medvik, K., Battaglia, C. A., Landay, A. L., Pahwa, S., Fischl, M. A., Asmuth, D. M., Tenorio, A. R., Altman, J. D., Fox, L., Moir, S., Malaspina, A., Morre, M., Buffet, R., Silvestri, G., Lederman, M. M.; ACTG 5214 Study Team. (2009) IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 113, 6304-6314.
80. Unsinger, J., McGlynn, M., Kasten, K. R., Hoekzema, A. S., Watanabe, E., Muenzer, J. T., McDonough, J. S., Tschoep, J., Ferguson, T. A., Mc-Dunn, J. E., Morre, M., Hildeman, D. A., Caldwell, C. C., Hotchkiss, R. S. (2010) IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J. Immunol. 184, 3768-3779.
81. Kasten, K. R., Prakash, P. S., Unsinger, J., Goetzman, H. S., England, L. G., Cave, C. M., Seitz, A. P., Mazuski, C. N., Zhou, T. T., Morre, M., Hotchkiss, R. S., Hildeman, D. A., Caldwell, C. C. (2010) Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through γδ T-cell IL-17 production in a murine model of sepsis. Infect. Immun. 78, 4714-4722.
82. Xie, M. H., Aggarwal, S., Ho, W. H., Foster, J., Zhang, Z., Stinson, J., Wood, W. I., Goddard, A. D., Gurney, A. L. (2000) Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptorrelated proteins CRF2-4 and IL-22R. J. Biol. Chem. 275, 31335-31339.
83. Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T. K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., Gorman, D. M., Bazan, J. F., Kastelein, R. A. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490.
84. Carriere, V., Roussel, L., Ortega, N., Lacorre, D. A., Americh, L., Aguilar, L., Bouche, G., Girard, J. P. (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 104, 282-287.
85. Ohno, T., Oboki, K., Kajiwara, N., Morii, E., Aozasa, K., Flavell, R. A., Okumura, K., Saito, H., Nakae, S. (2009) Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J. Immunol. 183, 7890-7897.
86. Chackerian, A. A., Oldham, E. R., Murphy, E. E., Schmitz, J., Pflanz, S., Kastelein, R. A. (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179, 2551-2555.
87. Kurowska-Stolarska, M., Kewin, P., Murphy, G., Russo, R. C., Stolarski, B., Garcia, C. C., Komai-Koma, M., Pitman, N., Li, Y., Niedbala, W., McKenzie, A. N., Teixeira, M. M., Liew, F. Y., Xu, D. (2008) IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181, 4780-4790.
88. Komai-Koma, M., Xu, D., Li, Y., McKenzie, A. N. J., McInnes, I. B., Liew, F. Y. (2007) IL-33 is a chemoattractant for human Th2 cells. Euro. J. Immunol. 37, 2779-2786.
89. Ali, S., Huber, M., Kollewe, C., Bischoff, S. C., Falk, W., Martin, M. U. (2007) IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc. Natl. Acad. Sci. USA 104, 18660-18665.
90. Kurowska-Stolarska, M., Stolarski, B., Kewin, P., Murphy, G., Corrigan, C. J., Ying, S., Pitman, N., Mirchandani, A., Rana, B., van Rooijen, N., Shepherd, M., McSharry, C., McInnes, I. B., Xu, D., Liew, F. Y. (2009) IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 183, 6469-6477.
91. Iwahana, H., Yanagisawa, K., Ito-Kosaka, A., Kuroiwa, K., Tago, K., Komatsu, N., Katashima, R., Itakura, M., Tominaga, S. (1999) Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur. J. Biochem. 264, 397-406.
92. Hoogerwerf, J. J., Tanck, M. W. T., Van Zoelen, M. A. D., Wittebole, X., Laterre, P. F., Van Der Poll, T. (2010) Soluble ST2 plasma concentrations predict mortality in severe sepsis. Inten. Care Med. 36, 630-637.
93. Gibot, S. (2006) Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia and severe sepsis. Semin. Respir. Crit. Care Med. 27, 29-33.
94. Bouchon, A., Facchetti, F., Weigand, M. A., Colonna, M. (2001) TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410, 1103-1107.
95. Wang, F., Liu, S., Wu, S., Zhu, Q., Ou, G., Liu, C., Wang, Y., Liao, Y., Sun, Z. (2012) Blocking TREM-1 signaling prolongs survival of mice with Pseudomonas aeruginosa induced sepsis. Cell. Immunol. 272, 251-258.
96. Andersson, U., Erlandsson-Harris, H., Yang, H., Tracey, K. J. (2002) HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 72, 1084-1091.
97. Wang, H., Vishnubhakat, J. M., Bloom, O., Zhang, M., Ombrellino, M., Sama, A., Tracey, K. J. (1999) Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126, 389-392.
98. Yang, H., Tracey, K. J. (2010) Targeting HMGB1 in inflammation. Biochim. Biophys. Acta 1799, 149-156.
99. Gardella, S., Andrei, C., Ferrera, D., Lotti, L. V., Torrisi, M. R., Bianchi, M. E., Rubartelli, A. (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3, 995-1001.
100. Bonaldi, T., Talamo, F., Scaffidi, P., Ferrera, D., Porto, A., Bachi, A., Rubartelli, A., Agresti, A., Bianchi, M. E. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22, 5551-5560.
101. Oh, Y. J., Youn, J. H., Ji, Y., Lee, S. E., Lim, K. J., Choi, J. E., Shin, J. S. (2009) HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J. Immunol. 182, 5800-5809.
102. Scaffidi, P., Misteli, T., Bianchi, M. E. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195.
103. Bell, C. W., Jiang, W., Reich III, C. F., Pisetsky, D. S. (2006) The extracellular release of HMGB1 during apoptotic cell death. Am. J. Physiol. Cell Physiol. 291, C1318-C1325.
104. Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., Manogue, K. R., Faist, E., Abraham, E., Andersson, J., Andersson, U., Molina, P. E., Abumrad, N. N., Sama, A., Tracey, K. J. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251.
105. Sappington, P. L., Yang, R., Yang, H., Tracey, K. J., Delude, R. L., Fink, M. P. (2002) HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 123, 790-802.
106. Wang, H., Liao, H., Ochani, M., Justiniani, M., Lin, X., Yang, L., Al-Abed, Y., Wang, H., Metz, C., Miller, E. J., Tracey, K. J., Ulloa, L. (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10, 1216-1221.
107. Ulloa, L., Ochani, M., Yang, H., Tanovic, M., Halperin, D., Yang, R., Czura, C. J., Fink, M. P., Tracey, K. J. (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. USA 99, 12351-12356.
108. Kawahara, K., Hashiguchi, T., Masuda, K., Saniabadi, A. R., Kikuchi, K., Tancharoen, S., Ito, T., Miura, N., Morimoto, Y., Biswas, K. K., Nawa, Y., Meng, X., Oyama, Y., Takenouchi, K., Shrestha, B., Sameshima, H., Shimizu, T., Adachi, T., Adachi, M., Maruyama, I. (2009) Mechanism of HMGB1 release inhibition from RAW264.7 cells by oleanolic acid in Prunus mume Sieb. et Zucc. Int. J. Mol. Med. 23, 615-620.
109. Kato, S., Hussein, M. H., Kakita, H., Goto, T., Daoud, G. A., Kato, T., Sugiura, T., Nobata, M., Nakajima, Y., Endo, T., Mizuno, K., Ito, T., Kato, I., Suzuki, S., Togari, H. (2009) Edaravone, a novel free radical scavenger, reduces high-mobility group box 1 and prolongs survival in a neonatal sepsis model. Shock 32, 586-592.
110. Li, W., Ashok, M., Li, J., Yang, H., Sama, A. E., Wang, H. (2007) A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One 2, e1153.
111. Shinohara, M. L., Kim, H. J., Kim, J. H., Garcia, V. A., Cantor, H. (2008a) Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc. Natl. Acad. Sci. USA 105, 7235-7239.
112. Smith, L. L., Giachelli, C. M. (1998) Structural requirements for α 9 β 1-mediated adhesion and migration to thrombin-cleaved osteopontin. Exp. Cell. Res. 242, 351-360.
113. Bayless, K. J., Davis, G. E. (2001) Identification of dual α4 β1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin. J. Biol. Chem. 276, 13483-13489.
114. Weber, G. F., Zawaideh, S., Hikita, S., Kumar, V. A., Cantor, H., Ashkar, S. (2002) Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J. Leukoc. Biol. 72, 752-761.
115. Nystrom, T., Duner, P., Hultgardh-Nilsson, A. (2007) A constitutive endogenous osteopontin production is important for macrophage function and differentiation. Exp. Cell. Res. 313, 1149-1160.
116. Ashkar, S., Weber, G. F., Panoutsakopoulou, V., Sanchirico, M. E., Jansson, M., Zawaideh, S., Rittling, S. R., Denhardt, D. T., Glimcher, M. J., Cantor, H. (2000) Eta-1 (osteopontin): an early component of type-1 (cellmediated) immunity. Science 287, 860-864.
117. Koh, A., da Silva, A. P., Bansal, A. K., Bansal, M., Sun, C., Lee, H., Glogauer, M., Sodek, J., Zohar, R. (2007) Role of osteopontin in neutrophil function. Immunology 122, 466-475.
118. Shinohara, M. L., Jansson, M., Hwang, E. S., Werneck, M. B., Glimcher, L. H., Cantor, H. (2005) T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc. Natl. Acad. Sci. USA 102, 17101-17106.
119. Diao, H., Kon, S., Iwabuchi, K., Kimura, C., Morimoto, J., Ito, D., Segawa, T., Maeda, M., Hamuro, J., Nakayama, T., Taniguchi, M., Yagita, H., Van Kaer, L., Onoe, K., Denhardt, D., Rittling, S., Uede, T. (2004) Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21, 539-550.
120. Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., Burtin, P. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883-897.
121. Mullershausen, F., Zecri, F., Cetin, C., Billich, A., Guerini, D., Seuwen, K. (2009) Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat. Chem. Biol. 5, 428-434.
122. Chiang, N., Arita, M., Serhan, C. N. (2005) Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot. Essent. Fatty Acids 73, 163-177.
123. Walker, J., Dichter, E., Lacorte, G., Kerner, D., Spur, B., Rodriguez, A., Yin, K. (2011) Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis. Shock 36, 410-416.
124. Lago, F., Dieguez, C., Gómez-Reino, J., Gualillo, O. (2007) Adipokines as emerging mediators of immune response and inflammation. Nat. Clin. Pract. Rheumatol. 3, 716-724.
125. Ouchi, N., Kihara, S., Arita, Y., Okamoto, Y., Maeda, K., Kuriyama, H., Hotta, K., Nishida, M., Takahashi, M., Muraguchi, M., Ohmoto, Y., Nakamura, T., Yamashita, S., Funahashi, T., Matsuzawa, Y. (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 102, 1296-1301.
126. Tilg, H., Wolf, A. M. (2005) Adiponectin: a key fat-derived molecule regulating inflammation. Expert Opin. Ther. Targets 9, 245-251.
127. Inui, A., Asakawa, A., Bowers, C. Y., Mantovani, G., Laviano, A., Meguid, M. M., Fujimiya, M. (2004) Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J. 18, 439-456.
128. Jacob, A., Rajan, D., Pathickal, B., Balouch, I., Hartman, A., Wu, R., Zhou, M., Wang, P. (2010) The inhibitory effect of ghrelin on sepsisinduced inflammation is mediated by the MAPK phosphatase-1. Int. J. Mol. Med. 25, 159-164.
129. Shah, K. G., Wu, R., Jacob, A., Blau, S. A., Ji, Y., Dong, W., Marini, C. P., Ravikumar, T. S., Coppa, G. F., Wang, P. (2009) Human ghrelin ameliorates organ injury and improves survival after radiation injury combined with severe sepsis. Mol. Med. 15, 407-414.
130. Jacob, A., Shah, K. G., Wu, R., Wang, P. (2010) Ghrelin as a novel therapy for radiation combined injury. Mol. Med. 16, 137-143.
131. Kitamura, K., Kangawa, K., Kawamoto, M., Ichiki, Y., Nakamura, S., Matsuo, H., Eto. T. (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 192, 553-560.
132. Nishio, K., Akai, Y., Murao, Y., Doi, N., Ueda, S., Tabuse, H., Miyamoto, S., Dohi, K., Minamino, N., Shoji, H., Kitamura, K., Kangawa, K., Matsuo, H. (1997) Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit. Care Med. 25, 953-957.
133. Fujioka, S. (2001) Increased plasma concentration of adrenomedullin during and after major surgery. Surg. Today 31, 575-579.
134. McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., Foord, S. M. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393, 333-339.
135. Wu, Z., Lauer, T. W., Sick, A., Hackett, S. F., Campochiaro, P. A. (2007) Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3. J. Biol. Chem. 282, 22414-22425.
136. Lukiw, W. J., Zhao, Y., Cui, J. G. (2008) An NF-κ B-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J. Biol. Chem. 283, 31315-31322.
137. Yang, S., Zhou, M., Chaudry, I. H., Wang, P. (2002) Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: role of adrenomedullin and adrenomedullin binding protein-1. Ann. Surg. 236, 625-633.
138. Wu, R., Zhou, M., Wang, P. (2003) Adrenomedullin and adrenomedullin binding protein-1 downregulate TNF-κ in macrophage cell line and rat Kupffer cells. Regul. Pept. 112, 19-26.
139. Miksa, M., Wu, R., Cui, X., Dong, W., Das, P., Simms, H. H., Ravikumar, T. S., Wang, P. (2007) Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-γ. J. Immunol. 179, 6263-6272.
140. lez-Rey, E., Chorny, A., Varela, N., Robledo, G., Delgado, M. (2006) Urocortin and adrenomedullin prevent lethal endotoxemia by downregulating the inflammatory response. Am. J. Pathol. 168, 1921-1930.
141. Saito, Y., Nakagawa, C., Uchida, H., Sasaki, F., Sakakibara, H. (2001) Adrenomedullin suppresses fMLP-induced upregulation of CD11b of human neutrophils. Inflammation 25, 197-201.
142. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., Masaki, T. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415.
143. Kedzierski, R. M., Yanagisawa, M. (2001) Endothelin system: the double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol. 41, 851-876.
144. Guarda, E., Myers, P. R., Brilla, C. G., Tyagi, S. C., Weber, K. T. (1993) Effects of endothelin on collagen turnover in cardiac fibroblasts. Cardiovasc. Res. 27, 1004-1008.
145. Tschaikowsky, K., Sagner, S., Lehnert, N., Kaul, M., Ritter, J. (2000) Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit. Care Med. 28, 1854-1860.
146. Figueras-Aloy, J., Gomez-Lopez, L., Rodriguez-Miguelez, J. M., Jordán-García, Y., Salvia-Roiges, M. D., Jiménez, W., Carbonell-Estrany, X. (2004) Plasma endothelin-1 and clinical manifestations of neonatal sepsis. J. Perinat. Med. 32, 522-526.
147. Piechota, M., Banach, M., Irzmanski, R., Barylski, M., Piechota-Urbanska, M., Kowalski, J., Pawlicki, L. (2007) Plasma endothelin-1 levels in septic patients. J. Intensive Care Med. 22, 232-239.
148. Pierrakos, C., Vincent, J. L. (2010) Sepsis biomarkers: a review. Crit. Care 14, R15.
149. Miksa, M., Wu, R., Dong, W., Das, P., Yang, D., Wang, P. (2006) Dendritic cell-derived exosomes containing milk fat globule epidermal growth factor-factor VIII attenuate proinflammatory responses in sepsis. Shock 25, 586-593.
150. Aziz, M., Jacob, A., Matsuda, A., Wang, P. (2011) Review: milk fat globule-EGF factor 8 expression, function and plausible signal transduction in resolving inflammation. Apoptosis 16, 1077-1086.
151. Aziz, M., Jacob, A., Wu, R., Matsuda, A., Zhou, M., Dong, W., Wang, P. (2011) MFG-E8 attenuates LPS-induced TNF-κ production in macrophages via STAT3-mediated SOCS3 activation. PLoS One 6, e27685.
152. Fink, M. P. (2008) Animal models of sepsis and its complications. Kidney Int. 74, 991-993.
153. McNamara, M. J., Norton, J. A., Nauta, R. J., Alexander, H. R. (1993) Interleukin-1 receptor antibody (IL-1rab) protection and treatment against lethal endotoxemia in mice. J. Surg. Res. 54, 316-321.
154. Fisher C. J., Jr., Dhainaut, J. F., Opal, S. M., Pribble, J. P., Balk, R. A., Slotman, G. J., Iberti, T. J., Rackow, E. C., Shapiro, M. J., Greenman, R. L. (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271, 1836-1843.
155. Doi, K., Leelahavanichkul, A., Yuen, P. S., Star, R. A. (2009) Animal models of sepsis and sepsis-induced kidney injury. J. Clin. Invest. 119, 2868-2878.
156. Tracey, K. J., Fong, Y., Hesse, D. G., Manogue, K. R., Lee, A. T., Kuo, G. C., Lowry, S. F., Cerami, A. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662-664.
157. Fisher C. J., Jr., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M., Benjamin, E. (1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334, 1697-1702.
158. Marshall, J. C. (2003) Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat. Rev. Drug Discov. 2, 391-405.